[go: up one dir, main page]

NI201400125A - Antagonistas de st2l y métodos de uso - Google Patents

Antagonistas de st2l y métodos de uso

Info

Publication number
NI201400125A
NI201400125A NI201400125A NI201400125A NI201400125A NI 201400125 A NI201400125 A NI 201400125A NI 201400125 A NI201400125 A NI 201400125A NI 201400125 A NI201400125 A NI 201400125A NI 201400125 A NI201400125 A NI 201400125A
Authority
NI
Nicaragua
Prior art keywords
methods
antagonists
st2l
st2l antagonists
fragments
Prior art date
Application number
NI201400125A
Other languages
English (en)
Inventor
Duffy Karen
Healy Catherine
Lamb Roberta
Malaviya Ravi
Pratta Michael
Fursov Natalie
Luo Jinquan
Naso Michael
Tornetta Mark
Wheeler John
Wu Sheng-Jiun
Hall Leroy
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of NI201400125A publication Critical patent/NI201400125A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)

Abstract

La presente invención se refiere a antagonistas de ST2L, polinucleótidos que codifican los antagonistas o fragmentos de los mismos, y métodos para preparar y utilizar lo anterior.
NI201400125A 2012-04-30 2014-10-29 Antagonistas de st2l y métodos de uso NI201400125A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640238P 2012-04-30 2012-04-30
US201261640407P 2012-04-30 2012-04-30
US13/798,204 US9090694B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists
US13/798,226 US9212227B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

Publications (1)

Publication Number Publication Date
NI201400125A true NI201400125A (es) 2016-11-30

Family

ID=49477497

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400125A NI201400125A (es) 2012-04-30 2014-10-29 Antagonistas de st2l y métodos de uso

Country Status (37)

Country Link
US (4) US9212227B2 (es)
EP (2) EP3597219A1 (es)
JP (3) JP6283354B2 (es)
KR (2) KR20150008152A (es)
CN (2) CN107098973A (es)
AR (1) AR090909A1 (es)
AU (2) AU2013256645B2 (es)
BR (1) BR112014027165A2 (es)
CA (1) CA2871948C (es)
CL (1) CL2014002955A1 (es)
CO (1) CO7240389A2 (es)
CR (1) CR20140488A (es)
CY (1) CY1122308T1 (es)
DK (1) DK2844292T3 (es)
EA (2) EA201891264A3 (es)
EC (1) ECSP14025178A (es)
ES (1) ES2755094T3 (es)
HR (1) HRP20191884T1 (es)
HU (1) HUE045864T2 (es)
IL (2) IL235401B (es)
LT (1) LT2844292T (es)
MX (2) MX358134B (es)
MY (1) MY166062A (es)
NI (1) NI201400125A (es)
NZ (3) NZ740221A (es)
PE (1) PE20150641A1 (es)
PH (2) PH12014502435A1 (es)
PL (1) PL2844292T3 (es)
PT (1) PT2844292T (es)
RS (1) RS59511B1 (es)
SG (2) SG11201407028WA (es)
SI (1) SI2844292T1 (es)
SM (1) SMT201900639T1 (es)
TW (3) TWI687440B (es)
UA (1) UA118336C2 (es)
UY (1) UY34774A (es)
WO (1) WO2013165894A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
PT2506871T (pt) * 2009-11-30 2016-11-07 Janssen Biotech Inc Mutantes de fc de anticorpos com funções efetoras inutilizadas
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
MX2016009047A (es) 2014-01-10 2017-04-13 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (il-33).
WO2015164354A1 (en) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
EP3157634B1 (en) 2014-06-23 2018-12-12 Bionomics, Inc. Antibodies that bind lgr4
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
EP3265107B1 (en) * 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
AU2017208099A1 (en) * 2016-01-14 2018-08-09 Anaptysbio, Inc. Inhibition of allergic reaction using an IL-33 inhibitor
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US20190225682A1 (en) * 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
EP3506920A4 (en) * 2016-09-02 2020-05-27 180 Therapeutics LP METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3580240A1 (en) 2017-02-10 2019-12-18 H. Hoffnabb-La Roche Ag Anti-tryptase antibodies, compositions thereof, and uses thereof
CN110382542B (zh) * 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
IL314591A (en) 2017-04-13 2024-09-01 Regeneron Pharma Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
AR114001A1 (es) 2017-12-21 2020-07-08 Hoffmann La Roche Anticuerpos que se unen a hla- a2 / wt1
BR112020016172A2 (pt) 2018-02-09 2020-12-15 Genentech, Inc. Métodos de tratamento, métodos para determinar, métodos para selecionar uma terapia, métodos para avaliar uma resposta e monitorar a resposta, kits para identificar um paciente, agentes selecionados, agentes para uso, uso de um agente selecionado e uso de um antagonista
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
US20210403579A1 (en) * 2018-10-31 2021-12-30 Delinia, Inc. Multivalent regulatory t cell modulators
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
JP2023501316A (ja) 2019-11-04 2023-01-18 メドイミューン・リミテッド 腎機能障害を治療するための抗ｉｌ－３３治療薬
EP4054711A1 (en) 2019-11-04 2022-09-14 MedImmune Limited Methods of using il-33 antagonists
JP2023516497A (ja) 2020-03-13 2023-04-19 メドイミューン・リミテッド Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法
JP7767298B2 (ja) 2020-03-13 2025-11-11 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
WO2021204707A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
EP4151654A4 (en) 2020-05-12 2024-11-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2 antigen binding protein
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
TW202322850A (zh) * 2021-08-05 2023-06-16 美商美國禮來大藥廠 抗體最佳化
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
KR20240161653A (ko) * 2022-02-24 2024-11-12 시노맙 바이오사이언스 리미티드 알라르민에 대한 이중 특이적 결합 단백질 및 이의 용도
CN115838425B (zh) * 2022-08-31 2024-06-18 首都医科大学 一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use
CN119841936B (zh) * 2024-12-30 2025-09-30 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 抗非洲猪瘟病毒p72蛋白中和性单克隆抗体5d2及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
DE69738806D1 (de) 1996-10-10 2008-08-14 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
DE60143544D1 (de) * 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
BRPI0507236A (pt) * 2004-01-30 2007-06-26 Peplin Biolipids Pty Ltd método para o tratamento ou profilaxia de uma condição, e, composto
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20090060920A1 (en) 2004-11-15 2009-03-05 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
PL2059535T3 (pl) 2006-08-18 2014-04-30 Novartis Ag Przeciwciało specyficzne względem PRLR i jego zastosowanie
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
EP2069784A4 (en) 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8817596B2 (en) 2009-01-09 2014-08-26 Futurewei Technologies, Inc. Protecting ingress and egress of a label switched path
US7879978B2 (en) * 2009-03-31 2011-02-01 Centocor Ortho Biotech, Inc. Macaca fascicularis ST2L
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PT2506871T (pt) * 2009-11-30 2016-11-07 Janssen Biotech Inc Mutantes de fc de anticorpos com funções efetoras inutilizadas
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
AU2011235232B2 (en) 2010-03-30 2015-05-21 Janssen Biotech Inc. Humanized IL-25 antibodies
ES2571994T3 (es) 2010-04-09 2016-05-27 Critical Care Diagnostics Inc Anticuerpos contra ST-2 humana soluble y ensayos
LT2560993T (lt) 2010-04-20 2024-10-10 Genmab A/S Baltymai, kurių sudėtyje yra heterodimerinio antikūno fc, ir jų gamybos būdai
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
US8785153B2 (en) 2011-02-23 2014-07-22 Hoffmann-La Roche, Inc. Antibodies against human IL33R and uses thereof
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2

Also Published As

Publication number Publication date
ES2755094T3 (es) 2020-04-21
TWI700299B (zh) 2020-08-01
SG11201407028WA (en) 2015-01-29
CO7240389A2 (es) 2015-04-17
AU2013256645B2 (en) 2017-06-08
WO2013165894A2 (en) 2013-11-07
CL2014002955A1 (es) 2015-01-16
JP6283354B2 (ja) 2018-02-21
US20170066831A1 (en) 2017-03-09
CN107098973A (zh) 2017-08-29
KR102147140B1 (ko) 2020-08-25
TW201730216A (zh) 2017-09-01
EA201891264A3 (ru) 2019-02-28
EP2844292A4 (en) 2016-05-25
SG10201608525SA (en) 2016-12-29
AR090909A1 (es) 2014-12-17
IL235401B (en) 2020-10-29
EP2844292A2 (en) 2015-03-11
US9090694B2 (en) 2015-07-28
NZ729913A (en) 2018-07-27
DK2844292T3 (da) 2019-10-21
PH12014502435A1 (en) 2015-01-12
CA2871948C (en) 2020-09-08
HK1208182A1 (en) 2016-02-26
SMT201900639T1 (it) 2020-01-14
CY1122308T1 (el) 2021-01-27
CR20140488A (es) 2015-01-12
EP2844292B1 (en) 2019-08-21
US9951137B2 (en) 2018-04-24
PT2844292T (pt) 2019-11-26
IL254569A0 (en) 2017-11-30
RS59511B1 (sr) 2019-12-31
US20190062439A1 (en) 2019-02-28
PE20150641A1 (es) 2015-05-11
MX358134B (es) 2018-08-06
PH12018501839A1 (en) 2020-09-14
EA201891264A2 (ru) 2018-11-30
AU2017202610A1 (en) 2017-05-11
HRP20191884T1 (hr) 2020-02-07
MY166062A (en) 2018-05-22
PL2844292T3 (pl) 2020-03-31
IL235401A0 (en) 2014-12-31
NZ702136A (en) 2017-03-31
IL254569B (en) 2020-10-29
ECSP14025178A (es) 2015-08-31
US20130336980A1 (en) 2013-12-19
AU2017202610B2 (en) 2019-06-13
TW202019969A (zh) 2020-06-01
EA031047B1 (ru) 2018-11-30
BR112014027165A2 (pt) 2017-07-18
US20130287777A1 (en) 2013-10-31
UA118336C2 (uk) 2019-01-10
JP2019162136A (ja) 2019-09-26
NZ740221A (en) 2019-11-29
WO2013165894A3 (en) 2014-03-27
AU2017202610B9 (en) 2019-06-20
MX2018009430A (es) 2020-09-02
US9212227B2 (en) 2015-12-15
CA2871948A1 (en) 2013-11-07
MX2014013200A (es) 2014-12-08
LT2844292T (lt) 2019-11-25
JP6622274B2 (ja) 2019-12-18
JP2018064560A (ja) 2018-04-26
TW201345923A (zh) 2013-11-16
TWI589588B (zh) 2017-07-01
SI2844292T1 (sl) 2020-02-28
KR20150008152A (ko) 2015-01-21
JP2015516817A (ja) 2015-06-18
EA201491996A1 (ru) 2015-04-30
KR20200037886A (ko) 2020-04-09
CN104411333B (zh) 2017-04-26
HUE045864T2 (hu) 2020-01-28
EP3597219A1 (en) 2020-01-22
UY34774A (es) 2013-11-29
AU2013256645A1 (en) 2014-11-13
TWI687440B (zh) 2020-03-11
CN104411333A (zh) 2015-03-11
US10450377B2 (en) 2019-10-22

Similar Documents

Publication Publication Date Title
NI201400125A (es) Antagonistas de st2l y métodos de uso
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
DOP2013000307A (es) Antagonistas de trpv4
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
UY34668A (es) COMPUESTOS EN BASE A PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
UY34697A (es) Métodos para preparar análogos de nucleótidos
BR112015002767A2 (pt) composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia
PT3177659T (pt) Compostos contendo azoto, adequados para uso na preparação de poliuretanos
CY1120481T1 (el) Kv1.3 ανταγωνιστες και μεθοδοι χρησης
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
DK3022274T3 (da) Fremgangsmåde til fremstilling af flammebeskyttede copolyamider, de ifølge denne opnåelige polyamidgarner samt disses anvendelse
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
DOP2016000105A (es) Anticuerpos anti-ccl17.
MX369290B (es) Inhibidores de fbx03.
BR112015017637A2 (pt) compósito plano, processo para produção de um compósito plano, recipiente, processo para a produção de um recipiente e uso de um compósito ou de um recipiente
MX2017008090A (es) Nuevos compuestos, su procedimiento de sintesis y su uso en medicina, asi como en cosmetica.
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso
UY34802A (es) ?suspensión acuosa que contiene polímeros adsorbibles sostenibles, un proceso para prepararla y su uso?.